GLP-1 has also been identified as an important regulator of inflammation and metabolic diseases and has been targeted as a therapeutic opportunity to improve cardiovascular and metabolic outcomes of patients with obesity and T2DM. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.